{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:07:11Z","timestamp":1789160831233,"version":"build-2803163510"},"reference-count":40,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:p>Post-traumatic stress disorder (PTSD) is a multifactorial neuropsychiatric condition characterized by persistent disturbances in fear processing, emotional regulation, and memory. Increasing evidence indicates that dysregulation of glutamatergic neurotransmission plays a crucial role in both the development and persistence of PTSD. Glutamate, the primary excitatory neurotransmitter in the central nervous system (CNS), is essential for synaptic plasticity and the formation of traumarelated memories. The aim of this study was to provide an integrated and critical synthesis of current knowledge on glutamatergic dysfunction in PTSD, with particular emphasis on its neurobiological, clinical, and therapeutic implications. This article is a narrative review of the literature published between 2017 and 2025 was conducted. Databases such as PubMed, Scopus, and Web of Science were searched for experimental, clinical, and neuroimaging studies investigating glutamatergic signaling in PTSD. The reviewed studies indicate that chronic stress disrupts glutamate homeostasis, leading to increased extracellular glutamate concentrations and impaired synaptic clearance. These alterations result in excessive activation of ionotropic receptors, particularly N-methyl-D-aspartate (NMDA) receptors and \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, promoting calcium influx and neuronal dysfunction. Such processes affect key brain regions, including the amygdala, hippocampus, and prefrontal cortex, contributing to impaired fear extinction and heightened emotional reactivity. Importantly, glutamatergic dysregulation does not occur in isolation but interacts dynamically with neuroinflammatory pathways, altered inhibitory transmission, and dysregulation of the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis. In conclusion, altered glutamatergic neurotransmission represents a central mechanism in PTSD pathophysiology. Its role in synaptic plasticity, neuronal vulnerability, and network dysregulation highlights its potential relevance as a diagnostic and therapeutic target. Future research should focus on integrating glutamate-related biomarkers with mechanism-based therapeutic interventions in order to improve diagnostic precision and treatment outcomes in PTSD<\/jats:p>","DOI":"10.36740\/merkur202604120","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:17:36Z","timestamp":1789157856000},"page":"526","source":"Crossref","is-referenced-by-count":0,"title":["Altered glutamatergic neurotransmission in the development  and maintenance of PTSD"],"prefix":"10.36740","volume":"54","author":[{"given":"Ewa Alicja","family":"Og\u0142odek","sequence":"first","affiliation":[{"name":"COLLEGIUM MEDICUM, JAN D\u0141UGOSZ UNIVERSITY, CZESTOCHOWA, POLAND"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Paraniak-Gieszczyk B, Og\u0142odek EA. Neurobiological correlates of coping strategies in PTSD: the role of IGF-1, CASP-9, nNOS, and IL-10 based on Brief-COPE assessment. Curr Issues Mol Biol. 2025;47:868. doi:10.3390\/cimb47100868.","DOI":"10.3390\/cimb47100868"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Uniyal A, Singh R, Akhtar A, et al. Pharmacological rewriting of fear memories: a beacon for post-traumatic stress disorder. Eur J Pharmacol. 2020;870:172824. doi:10.1016\/j.ejphar.2019.172824.","DOI":"10.1016\/j.ejphar.2019.172824"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Paraniak-Gieszczyk B, Og\u0142odek EA. Impact of post-traumatic stress disorder duration on volumetric and microstructural parameters of the hippocampus, amygdala, and prefrontal cortex: a multiparametric magnetic resonance imaging study with correlation analysis. J Clin Med. 2025;14:7242. doi:10.3390\/jcm14207242.","DOI":"10.3390\/jcm14207242"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Harnett NG, Wood KH, Ference EW 3rd, et al. Glutamate\/glutamine concentrations in the dorsal anterior cingulate vary with post-traumatic stress disorder symptoms. J Psychiatr Res. 2017;91:169-176. doi:10.1016\/j.jpsychires.2017.04.010.","DOI":"10.1016\/j.jpsychires.2017.04.010"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. von Engelhardt J. AMPA receptor auxiliary proteins of the CKAMP family. Int J Mol Sci. 2019;20:1460. doi:10.3390\/ijms20061460.","DOI":"10.3390\/ijms20061460"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Grzesi\u0144ska AD. The involvement of the endocannabinoid, glutamatergic, and GABAergic systems in PTSD. Int J Mol Sci. 2025;26:5929. doi:10.3390\/ijms26135929.","DOI":"10.3390\/ijms26135929"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Zhang G, Huang S, Wei M, et al. Excitatory amino acid transporters as therapeutic targets in the treatment of neurological disorders: their roles and therapeutic prospects. Neurochem Res. 2025;50:155. doi:10.1007\/s11064-025-04400-3.","DOI":"10.1007\/s11064-025-04400-3"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Og\u0142odek EA, Just MJ, Just K, et al. Peroxiredoxin-1 and peroxiredoxin-3 as indicators of sickness behaviour in patients with varying levels of depression severity. Eur Neuropsychopharmacol. 2017;27(Suppl 4):622-623. doi:10.1016\/S0924-977X(17)31177-X.","DOI":"10.1016\/S0924-977X(17)31177-X"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Qi J, Chen C, Gao Q. A JNK-regulated and IL-1\u03b2-dependent astrocyte-neuron signaling pathway in the spinal dorsal horn is essential for stress-induced hyperalgesia. Neural Plast. 2026;2026:e2791699. doi:10.1155\/np\/2791699.","DOI":"10.1155\/np\/2791699"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Og\u0142odek EA, Grzesi\u0144ska A, Paraniak-Gieszczyk B, et al. Embryological significance of glial cells in the central nervous system. Pol Merk Lek. 2024;52:739-743. doi:10.36740\/Merkur202406118.","DOI":"10.36740\/Merkur202406118"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Murayama R, Cai Y, Nakamura H, et al. Demyelination in psychiatric and neurological disorders: mechanisms, clinical impact, and novel therapeutic strategies. Neurosci Biobehav Rev. 2025;174:106209. doi:10.1016\/j.neubiorev.2025.106209.","DOI":"10.1016\/j.neubiorev.2025.106209"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Swanberg KM, Campos L, Abdallah CG, et al. Proton magnetic resonance spectroscopy in post-traumatic stress disorder: updated systematic review and meta-analysis. Chronic Stress. 2022;6:24705470221128004. doi:10.1177\/24705470221128004.","DOI":"10.1177\/24705470221128004"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Wo\u017any-Rasa\u0142a I, Og\u0142odek EA. Inflammatory and oxidative biological profiles in mental disorders: perspectives on diagnostics and personalized therapy. Int J Mol Sci. 2025;26:9654. doi:10.3390\/ijms26199654.","DOI":"10.3390\/ijms26199654"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Kadriu B, Musazzi L, Johnston JN, et al. Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road. Drug Discov Today. 2021;26:2816-2838. doi:10.1016\/j.drudis.2021.07.027.","DOI":"10.1016\/j.drudis.2021.07.027"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Grzesi\u0144ska AD. Biomarker-sleep correlations in PTSD: glutamine, glutathione, caspase-1, and BDNF levels assessed using the Pittsburgh Sleep Quality Index addendum. Curr Issues Mol Biol. 2025;47:814. doi:10.3390\/cimb47100814.","DOI":"10.3390\/cimb47100814"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Won W, Bhalla M, Lee JH, et al. Astrocytes as key regulators of neural signaling in health and disease. Annu Rev Neurosci. 2025;48:251-276. doi:10.1146\/annurev-neuro-112723-035356.","DOI":"10.1146\/annurev-neuro-112723-035356"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Wo\u017any-Rasa\u0142a I, Og\u0142odek EA. Biomolecular correlates of chronic affective dysregulation in PTSD: a combined assessment using the Cornell Dysthymia Rating Scale and serum markers SUMO1, MDA, CX3CL1, and UCHL1. Int J Mol Sci. 2025;26:10214. doi:10.3390\/ijms262010214.","DOI":"10.3390\/ijms262010214"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Dos Santos TG, Melgarejo AS, Ligabue-Braun R, et al. Phylogenetic and structural analyses of vesicular glutamate transporters. Mol Neurobiol. 2025;62:11962-11971. doi:10.1007\/s12035-025-05012-2.","DOI":"10.1007\/s12035-025-05012-2"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Rieskamp JD, Rosado-Burgos I, Christofi JE, et al. Excitatory amino acid transporter 1 supports adult hippocampal neural stem cell self-renewal. iScience. 2023;26:107068. doi:10.1016\/j.isci.2023.107068.","DOI":"10.1016\/j.isci.2023.107068"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Canul-Tec JC, Assal R, Cirri E, et al. Structure and allosteric inhibition of excitatory amino acid transporter 1. Nature. 2017;544:446-451. doi:10.1038\/nature22064.","DOI":"10.1038\/nature22064"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Wo\u017any-Rasa\u0142a I, Og\u0142odek EA. NLRP3 inflammasome in stress-related neuropsychiatric disorders: mechanisms of neuron\u2013microglia\u2013astrocyte crosstalk, HPA axis dysregulation, and therapeutic perspective. Biomolecules. 2025;15:1344. doi:10.3390\/biom15091344.","DOI":"10.3390\/biom15091344"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Nair JD, Wilkinson KA, Henley JM, et al. Kainate receptors and synaptic plasticity. Neuropharmacology. 2021;196:108540. doi:10.1016\/j.neuropharm.2021.108540.","DOI":"10.1016\/j.neuropharm.2021.108540"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Negrete-Diaz JV, Falcon-Moya R, Rodriguez-Moreno A. Kainate receptors: from synaptic activity to disease. FEBS J. 2022;289:5074-5088. doi:10.1111\/febs.16081.","DOI":"10.1111\/febs.16081"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Og\u0142odek EA, Just MJ, Mo\u015b DM, et al. Serum concentrations of iNOS and IL-33 in depressed patients with a history of suicide attempts. Eur Neuropsychopharmacol. 2017;27:650-651. doi:10.1016\/S0924-977X(17)31219-1.","DOI":"10.1016\/S0924-977X(17)31219-1"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Yu A, Lau AY. Glutamate and glycine binding to the NMDA receptor. Structure. 2018;26:1035-1043.e2. doi:10.1016\/j.str.2018.05.004.","DOI":"10.1016\/j.str.2018.05.004"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Zhang Y, Ye F, Zhang T, et al. Structural basis of ketamine action on human NMDA receptors. Nature. 2021;596:301-305. doi:10.1038\/s41586-021-03769-9.","DOI":"10.1038\/s41586-021-03769-9"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Mony L, Paoletti P. Mechanisms of NMDA receptor regulation. Curr Opin Neurobiol. 2023;83:102815. doi:10.1016\/j.conb.2023.102815.","DOI":"10.1016\/j.conb.2023.102815"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Seven AB, Barros-Alvarez X, de Lapeyriere M, et al. G-protein activation by a metabotropic glutamate receptor. Nature. 2021;595:450-454. doi:10.1038\/s41586-021-03680-3.","DOI":"10.1038\/s41586-021-03680-3"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Grzesi\u0144ska A, Og\u0142odek EA. Involvement of matrix metalloproteinases (MMP-2 and MMP-9), inflammasome NLRP3, and gamma-aminobutyric acid pathway in cellular mechanisms of neuroinflammation in PTSD. Int J Mol Sci. 2025;26:5662. doi:10.3390\/ijms26125662.","DOI":"10.3390\/ijms26125662"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Reiner A, Levitz J. Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert. Neuron. 2018;98:1080-1098. doi:10.1016\/j.neuron.2018.05.018.","DOI":"10.1016\/j.neuron.2018.05.018"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31. Satarker S, Bojja SL, Gurram PC, et al. Astrocytic glutamatergic transmission and its implications in neurodegenerative disorders. Cells. 2022;11:1139. doi:10.3390\/cells11071139.","DOI":"10.3390\/cells11071139"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Lalo U, Koh W, Lee CJ, et al. The tripartite glutamatergic synapse. Neuropharmacology. 2021;199:108758. doi:10.1016\/j.neuropharm.2021.108758.","DOI":"10.1016\/j.neuropharm.2021.108758"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33. Duman RS, Shinohara R, Fogaca MV, et al. Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. Mol Psychiatry. 2019;24:1816-1832. doi:10.1038\/s41380-019-0400-x.","DOI":"10.1038\/s41380-019-0400-x"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34. Jimenez-Trevino L, Gonzalez-Blanco L, Alvarez-Vazquez C, et al. Glutamine and new pharmacological targets to treat suicidal ideation. Curr Top Behav Neurosci. 2020;46:179-196. doi:10.1007\/7854_2020_168.","DOI":"10.1007\/7854_2020_168"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35. Nikayin S, Murphy E, Krystal JH, et al. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf. 2022;21:777-787. doi:10.1080\/14740338.2022.2066651.","DOI":"10.1080\/14740338.2022.2066651"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36. Da Costa Silva L, Laisney M, Charretier L, et al. Memory alterations in post-traumatic stress disorder. Biol Aujourdhui. 2023;217:55-64. doi:10.1051\/jbio\/2023018.","DOI":"10.1051\/jbio\/2023018"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37. Izquierdo I, Furini CR, Myskiw JC. Fear memory. Physiol Rev. 2016;96:695-750. doi:10.1152\/physrev.00018.2015.","DOI":"10.1152\/physrev.00018.2015"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38. Og\u0142odek EA, Just MJ, Mo\u015b DM, et al. Increased interleukin-1\u03b2 and interleukin-10 activity as a trait marker of depression. Eur Neuropsychopharmacol. 2017;27:623. doi:10.1016\/S0924-977X(17)31178-1.","DOI":"10.1016\/S0924-977X(17)31178-1"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. Wo\u017any-Rasa\u0142a I, Og\u0142odek EA. Biomarker correlations in PTSD: IL-18, IRE1, pERK, and ATF6 via Courtauld Emotional Control Scale. Int J Mol Sci. 2025;26:7506. doi:10.3390\/ijms26157506.","DOI":"10.3390\/ijms26157506"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40. Paraniak-Gieszczyk B, Og\u0142odek EA. Neurobiological and existential profiles in posttraumatic stress disorder: the role of serotonin, cortisol, noradrenaline, and IL-12 across chronicity and age. Int J Mol Sci. 2025;26:9636. doi:10.3390\/ijms26199636.","DOI":"10.3390\/ijms26199636"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:17:49Z","timestamp":1789157869000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2026i4net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202604120","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}